| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C1GALT1C1 |
| Uniprot No | Q96EU7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-318aa |
| 氨基酸序列 | MLSESSSFLKGVMLGSIFCALITMLGHIRIGHGNRMHHHEHHHLQAPNKEDILKISEDERMELSKSFRVYCIILVKPKDVSLWAAVKETWTKHCDKAEFFSSENVKVFESINMDTNDMWLMMRKAYKYAFDKYRDQYNWFFLARPTTFAIIENLKYFLLKKDPSQPFYLGHTIKSGDLEYVGMEGGIVLSVESMKRLNSLLNIPEKCPEQGGMIWKISEDKQLAVCLKYAGVFAENAEDADGKDVFNTKSVGLSIKEAMTYHPNQVVEGCCSDMAVTFNGLTPNQMHVMMYGVYRLRAFGHIFNDALVFLPPNGSDND |
| 分子量 | 60.72 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人C1GALT1C1(Cosmc)蛋白的3篇参考文献及其摘要概述：
1. **文献名称**: *Molecular cloning and characterization of a novel UDP-Gal:GalNAc-β1.3-galactosyltransferase (C1GALT1C1) essential for the synthesis of the core 1 O-glycan structure*
**作者**: Ju, T., et al.
**摘要**: 本研究首次报道了重组人C1GALT1C1(Cosmc)的克隆及功能分析，证实其作为分子伴侣对C1GALT1酶的活性调控至关重要，缺乏C1GALT1C1会导致核心1 O-聚糖合成缺陷。
2. **文献名称**: *Expression and functional characterization of recombinant human Cosmc in insect cells*
**作者**: Wang, Y., et al.
**摘要**: 作者利用昆虫细胞系统成功表达并纯化了重组人C1GALT1C1蛋白，验证其通过分子伴侣功能恢复突变细胞中C1GALT1的活性，并促进正常O-糖基化。
3. **文献名称**: *Structural insights into Cosmc-mediated quality control of O-glycosylation*
**作者**: Li, F., et al.
**摘要**: 通过晶体结构解析和生化实验，阐明重组C1GALT1C1与C1GALT1的相互作用机制，揭示其在维持糖基转移酶正确构象及糖基化保真性中的关键作用。
注：以上参考文献信息为模拟示例，实际引用时需核对具体文献来源及发表细节。
C1GALT1C1. also known as COSMC, is a crucial molecular chaperone required for the proper folding and functional activity of C1GALT1 (core 1 β1.3-galactosyltransferase), an enzyme essential for O-glycosylation. This protein plays a pivotal role in the biosynthesis of mucin-type O-glycans by stabilizing C1GALT1. which catalyzes the transfer of galactose to the Tn antigen (GalNAcα1-O-Ser/Thr) to form the core 1 structure (T antigen, Galβ1-3GalNAcα1-O-Ser/Thr). Without COSMC, C1GALT1 is degraded, leading to the accumulation of immature O-glycans associated with pathological conditions, including cancer, immune disorders, and congenital diseases like Tn syndrome.
Aberrant COSMC expression or mutations are linked to altered glycosylation patterns in malignancies such as colorectal, breast, and pancreatic cancers, promoting tumor progression and metastasis. Its critical role in maintaining glycosylation homeostasis has made it a focus in studies exploring disease mechanisms and therapeutic targets. Recombinant C1GALT1C1 protein is produced using expression systems (e.g., mammalian, insect cells) to study its structure-function relationships, interactome, and potential use in rescuing C1GALT1 activity in deficient models. Research also investigates its involvement in autoimmune disorders and immune evasion by pathogens. The development of recombinant COSMC enables biochemical assays, structural analyses, and preclinical evaluations for glycobiology-based therapies.
×
